Pharmacoeconomics of HIV-infection

Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system. It should be noted, that increase of HIV screening and number of patients on antiretroviral treatment are the most important features of the system. Nevertheless, experts note the continuing growth of the size of infected population and, that is more important, the escape of HIV-epidemics from the groups with risk behaviors to the general population, therefore it is necessary to further increase the effectiveness of activities against HIV-spreading. In particular, it is necessary to use more rational (in the context of both the effectiveness, safety and cost) in present settings medical technologies. Pharmacoeconomic analysis is an appropriate instrument for these challenges. However pharmacoeconomic analysis within HIV-infection, like within all other disease areas, has some planning and conducting specialties. We formulated some key aspects of pharmacoeconomic analysis within HIV-infection: need for modelling; use of several criteria (virological, immunological, clinical and epidemiological); consideration of adherence to the therapy; consideration of complications costs; consideration of indirect costs.

human immunodeficiency virus (HIV), antiretroviral therapy (ART), pharmacoeconomic analysis, modeling, cost analysis, effectiveness analysis, effectiveness criteria, budget impact analysis, adherence, epidemics, burden of the disease, вирус иммунодефицита человека (ВИЧ), антиретровирусная терапия (АРТ), фармакоэкономический анализ, моделирование, анализ затрат, анализ эффективности, критерии эффективности, анализ «влияния на бюджет», приверженность, эпидемия, бремя заболевания

1. Belyakova NA, Sizova NV, Toropov CE. Pharmacoeconomic analysis of highly active antiretroviral therapy of HIV-infection. The price of pharmacoresistance. VICH-infektsia i immunosupressii 2010; 2(4): 7–17 (in Russian).

2. Belyakova NA, Zaharova NG, Sizova NV. Economical and clinical aspects of HIV infection. St. Petersburg: Baltiyskiy meditsinskiy obrazovatelniy tsentr; 2014 (in Russian).

3. HIV-infection Information bulletin № 38. Federalniy nauchno-metodicheskiy tsentr po profilaktike i borbe so SPIDom FBUN CNIIE; 2013. Available from: http://hivrussia.ru/stat/bulletin.shtml#38 (in Russian).

4. Kulikov AYu., Litvinenko MM. Methodological basics of modeling in the pharmacoeconomic studies: different levels of complexity and different value of the results obtained. Farmakoekonomika: teoriya i praktika 2014; 2(2): 9–22 (in Russian).

5. Kulikov AYu, Babiy VV. Pharmacoeconomic analysis of Eviplera (Rilpivirine/Tenofovir/Emtricitabine) in the treatmant of HIV/AIDS in the Russian Federation. Farmakoekonomika: teoriya i praktika 2015; 3(1): 35–51 (in Russian).

6. National clinical recommendations on treatment and diagnostics HIV in adults. Moskovskiy gorodskoy tsentr po profilactike i borbe so SPIDom Departamenta zdravoochraneniya goroda Moskvi, GKUZ Moskovskoy oblasti «Tsentr po profilaktike i borbe so SPIDom i infektsionnymi zabolevaniyami»; 2014. Available from: http://www.nvassociation.ru/s/22092014.pdf (in Russian).

7. The minister Veronika Scvortsova took part in the Fourth Conference on HIV/AIDS in East Europe and Central Asia. Available from: http://www.rosminzdrav.ru/news/2014/05/12/1828-ministr-veronika-skvortsova- prinyalauchastie-v-chetvertoy-konferentsii-po-voprosam-vich-spida-v- vostochnoyevrope-i-tsentralnoy-azii (in Russian).

8. Information on HIV/AIDS in the Russian Federation. Federalny nauchnometodicheskiy tsentr po profilaktike i borbe so SPIDom FBUN CNIIE; 2014. Available from: http://hivrussia.ru/files/spravkaHIV2014.pdf (in Russian).

9. The strategy on counteraction of HIV-disease spreading in the Russian Federation 2014–2020. The overview of situation in the Russian Federation. Available from: http://www.hiv-2020.ru/review.html (in Russian).

10. Habriev RU, Kulikov AYu, Arinina EE. Methodological basics of pharmacoeconomic analysis. M.: Meditsina; 2011 (in Russian).

11. Yagudina RI, Babiy VV. Methodological basics of effectiveness analysis of health technologies in pharmacoeconomic studies. Farmakoekonomika: teoriya i praktika 2015; 3(1): 7–16 (in Russian).

12. Yagudina RI, Habriev RU, Pravdyuk NG. Health technologies assessment. M.: Meditsinskoe informatsionnoe agenstvo; 2013 (in Russian).

13. Antinori A, et al. Adherence in HIV-positive patients treated with singletablet regimens and multi-pill regimens: findings from the COMPACT study. Journal of International AIDS Society 2012; 15(Suppl. 4): 18098.

14. Bangsberg D, et al. REACH cohort adherence study. Adherence and efficacy results. 17th Conference on Retroviruses and Opportunistic Infections; 2010. Available from: http://www.hivnat.org/symposium/16th/download/D3P2.pdf.

15. Easterbrook PJ, et al. The role of mathematical modeling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines. AIDS 2014; 28(1): 85–92.

16. Nakagawa F, May M, Philips A. Life expectancy living with HIV: recent estimates and future implications. Current Opinion in Infectious Diseases 2013; 26(1): 17–25.

17. Patel P, Borkowf CB, Brooks JT, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 2014; 28(10): 1509–19.